These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

153 related articles for article (PubMed ID: 29098809)

  • 21. Modeling the full length HIV-1 Gag polyprotein reveals the role of its p6 subunit in viral maturation and the effect of non-cleavage site mutations in protease drug resistance.
    Su CT; Kwoh CK; Verma CS; Gan SK
    J Biomol Struct Dyn; 2018 Dec; 36(16):4366-4377. PubMed ID: 29237328
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Gag-protease coevolution shapes the outcome of lopinavir-inclusive treatment regimens in chronically infected HIV-1 subtype C patients.
    Marie V; Gordon M
    Bioinformatics; 2019 Sep; 35(18):3219-3223. PubMed ID: 30753326
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Elucidation of the Molecular Mechanism Driving Duplication of the HIV-1 PTAP Late Domain.
    Martins AN; Waheed AA; Ablan SD; Huang W; Newton A; Petropoulos CJ; Brindeiro RD; Freed EO
    J Virol; 2016 Jan; 90(2):768-79. PubMed ID: 26512081
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Impact of amino acid variations in Gag and protease of HIV type 1 CRF01_AE strains on drug susceptibility of virus to protease inhibitors.
    Jinnopat P; Isarangkura-na-ayuthaya P; Utachee P; Kitagawa Y; de Silva UC; Siripanyaphinyo U; Kameoka Y; Tokunaga K; Sawanpanyalert P; Ikuta K; Auwanit W; Kameoka M
    J Acquir Immune Defic Syndr; 2009 Nov; 52(3):320-8. PubMed ID: 19727001
    [TBL] [Abstract][Full Text] [Related]  

  • 25. HIV-1 protease inhibitor mutations affect the development of HIV-1 resistance to the maturation inhibitor bevirimat.
    Fun A; van Maarseveen NM; Pokorná J; Maas RE; Schipper PJ; Konvalinka J; Nijhuis M
    Retrovirology; 2011 Aug; 8():70. PubMed ID: 21864346
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Wide variation in susceptibility of transmitted/founder HIV-1 subtype C Isolates to protease inhibitors and association with in vitro replication efficiency.
    Sutherland KA; Collier DA; Claiborne DT; Prince JL; Deymier MJ; Goldstein RA; Hunter E; Gupta RK
    Sci Rep; 2016 Nov; 6():38153. PubMed ID: 27901085
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Impact of gag genetic determinants on virological outcome to boosted lopinavir-containing regimen in HIV-2-infected patients.
    Larrouy L; Vivot A; Charpentier C; Bénard A; Visseaux B; Damond F; Matheron S; Chene G; Brun-Vezinet F; Descamps D;
    AIDS; 2013 Jan; 27(1):69-80. PubMed ID: 23018441
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Prediction of drug-resistance in HIV-1 subtype C based on protease sequences from ART naive and first-line treatment failures in North India using genotypic and docking analysis.
    Toor JS; Sharma A; Kumar R; Gupta P; Garg P; Arora SK
    Antiviral Res; 2011 Nov; 92(2):213-8. PubMed ID: 21875619
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Drug resistance testing through remote genotyping and predicted treatment options in human immunodeficiency virus type 1 infected Tanzanian subjects failing first or second line antiretroviral therapy.
    Svärd J; Mugusi S; Mloka D; Neogi U; Meini G; Mugusi F; Incardona F; Zazzi M; Sönnerborg A
    PLoS One; 2017; 12(6):e0178942. PubMed ID: 28582463
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Drug resistance during indinavir therapy is caused by mutations in the protease gene and in its Gag substrate cleavage sites.
    Zhang YM; Imamichi H; Imamichi T; Lane HC; Falloon J; Vasudevachari MB; Salzman NP
    J Virol; 1997 Sep; 71(9):6662-70. PubMed ID: 9261388
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Mutational patterns and correlated amino acid substitutions in the HIV-1 protease after virological failure to nelfinavir- and lopinavir/ritonavir-based treatments.
    Garriga C; Pérez-Elías MJ; Delgado R; Ruiz L; Nájera R; Pumarola T; Alonso-Socas Mdel M; García-Bujalance S; Menéndez-Arias L;
    J Med Virol; 2007 Nov; 79(11):1617-28. PubMed ID: 17854027
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Prevalence of Transmitted Drug-Resistance Mutations and Polymorphisms in HIV-1 Reverse Transcriptase, Protease, and gp41 Sequences Among Recent Seroconverters in Southern Poland.
    Smoleń-Dzirba J; Rosińska M; Kruszyński P; Bratosiewicz-Wąsik J; Wojtyczka R; Janiec J; Szetela B; Beniowski M; Bociąga-Jasik M; Jabłonowska E; Wąsik TJ; The Cascade Collaboration In EuroCoord A
    Med Sci Monit; 2017 Feb; 23():682-694. PubMed ID: 28167814
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Transient HIV-1 Gag-protease interactions revealed by paramagnetic NMR suggest origins of compensatory drug resistance mutations.
    Deshmukh L; Louis JM; Ghirlando R; Clore GM
    Proc Natl Acad Sci U S A; 2016 Nov; 113(44):12456-12461. PubMed ID: 27791180
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Natural variation in HIV-1 protease, Gag p7 and p6, and protease cleavage sites within gag/pol polyproteins: amino acid substitutions in the absence of protease inhibitors in mothers and children infected by human immunodeficiency virus type 1.
    Barrie KA; Perez EE; Lamers SL; Farmerie WG; Dunn BM; Sleasman JW; Goodenow MM
    Virology; 1996 May; 219(2):407-16. PubMed ID: 8638406
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Effect of mutations in the human immunodeficiency virus type 1 protease on cleavage of the gp41 cytoplasmic tail.
    Waheed AA; Ablan SD; Sowder RC; Roser JD; Schaffner CP; Chertova E; Freed EO
    J Virol; 2010 Mar; 84(6):3121-6. PubMed ID: 20042499
    [TBL] [Abstract][Full Text] [Related]  

  • 36. HIV-1 Gag C-terminal amino acid substitutions emerging under selective pressure of protease inhibitors in patient populations infected with different HIV-1 subtypes.
    Li G; Verheyen J; Theys K; Piampongsant S; Van Laethem K; Vandamme AM
    Retrovirology; 2014 Sep; 11():79. PubMed ID: 25253273
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Impact of gag mutations on selection of darunavir resistance mutations in HIV-1 protease.
    Lambert-Niclot S; Flandre P; Malet I; Canestri A; Soulié C; Tubiana R; Brunet C; Wirden M; Katlama C; Calvez V; Marcelin AG
    J Antimicrob Chemother; 2008 Nov; 62(5):905-8. PubMed ID: 18765410
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Double trouble? Gag in conjunction with double insert in HIV protease contributes to reduced DRV susceptibility.
    Williams A; Basson A; Achilonu I; Dirr HW; Morris L; Sayed Y
    Biochem J; 2019 Jan; 476(2):375-384. PubMed ID: 30573649
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Failure of treatment with first-line lopinavir boosted with ritonavir can be explained by novel resistance pathways with protease mutation 76V.
    Nijhuis M; Wensing AM; Bierman WF; de Jong D; Kagan R; Fun A; Jaspers CA; Schurink KA; van Agtmael MA; Boucher CA
    J Infect Dis; 2009 Sep; 200(5):698-709. PubMed ID: 19627247
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Mutational Heterogeneity in p6 Gag Late Assembly (L) Domains in HIV-1 Subtype C Viruses from South Africa.
    Neogi U; Engelbrecht S; Claassen M; Jacobs GB; van Zyl G; Preiser W; Sonnerborg A
    AIDS Res Hum Retroviruses; 2016 Jan; 32(1):80-4. PubMed ID: 26413747
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.